Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason A Efstathiou

Showing results (21-30 of 278) with videos related to

Pageof 28
Sort By:
International Journal of Radiation Oncology, Biology, Physics|August 4, 2021
Standard Versus Hypofractionated Radiation Therapy for Bladder Cancer: New Insights, but Questions RemainBrian C Baumann, Paul Sargos, Jason A Efstathiou
The Lancet. Oncology|August 4, 2023
Radical cystectomy vs trimodality therapy for muscle-invasive bladder cancer: further extensive evaluation needed - Authors' replyAlexandre R Zlotta, Katherine Lajkosz, Jason A Efstathiou
The Lancet. Oncology|June 15, 2016
Beyond a moonshot: insurance coverage for proton therapyAnand Shah, Kelsey I Ricci, Jason A Efstathiou
JAMA Surgery|November 27, 2018
Utility of Bladder-Sparing Therapy vs Radical Cystectomy for Muscle-Invasive Bladder CancerJason A Efstathiou, Ananya Choudhury, Anne E Kiltie
European Urology|October 8, 2015
Reply from Authors re: Ronald C. Chen. Decisions Regarding Whether to Use Androgen Deprivation Therapy with Radiotherapy in Prostate Cancer: Is Cardiovascular Mortality the Most Relevant Outcome? Eur Urol 2016;69:211-2: Outcomes for Favorable and Unfavorable Intermediate Risk Prostate Cancer Patients Receiving Radiation Therapy With or Without Short-term Androgen Deprivation TherapyJustin C Voog, Rebecca Paulus, Jason A Efstathiou
European Urology|September 4, 2023
Reply to Thomas Seisen, Morgan Rouprêt, and Pierre Blanchard's Letter to the Editor re: Alexandre R. Zlotta, Leslie K. Ballas, Andrzej Niemierko, et al. Radical Cystectomy Versus Trimodality Therapy for Muscle-invasive Bladder Cancer: A Multi-institutional Propensity Score Matched and Weighted Analysis. Lancet Oncol 2023;24:669-81Alexandre R Zlotta, Katherine Lajkosz, Jason A Efstathiou
Oncology (Williston Park, N.Y.)|March 15, 2014
Proton radiotherapy for prostate cancer: how did we get here, and where do we go from here?James B Yu, Jason A Efstathiou, Justin E Bekelman
Asian Journal of Andrology|February 26, 2013
The opportunity cost of androgen suppression in locally advanced prostate cancerPhillip J Gray, Jason A Efstathiou, William U Shipley
Journal of Oncology Practice|August 15, 2013
Summary of oral abstract session B: innovating to improve care qualityJames A Hayman, Linda D Bosserman, Jason A Efstathiou
Hematology/Oncology Clinics of North America|April 4, 2015
Bladder preservation strategiesAshesh B Jani, Jason A Efstathiou, William U Shipley
Pageof 28

Showing results (21-30 of 278) with videos related to

Sort By:
Pageof 28
International Journal of Radiation Oncology, Biology, Physics|August 4, 2021
Standard Versus Hypofractionated Radiation Therapy for Bladder Cancer: New Insights, but Questions RemainBrian C Baumann, Paul Sargos, Jason A Efstathiou
The Lancet. Oncology|August 4, 2023
Radical cystectomy vs trimodality therapy for muscle-invasive bladder cancer: further extensive evaluation needed - Authors' replyAlexandre R Zlotta, Katherine Lajkosz, Jason A Efstathiou
The Lancet. Oncology|June 15, 2016
Beyond a moonshot: insurance coverage for proton therapyAnand Shah, Kelsey I Ricci, Jason A Efstathiou
JAMA Surgery|November 27, 2018
Utility of Bladder-Sparing Therapy vs Radical Cystectomy for Muscle-Invasive Bladder CancerJason A Efstathiou, Ananya Choudhury, Anne E Kiltie
European Urology|October 8, 2015
Reply from Authors re: Ronald C. Chen. Decisions Regarding Whether to Use Androgen Deprivation Therapy with Radiotherapy in Prostate Cancer: Is Cardiovascular Mortality the Most Relevant Outcome? Eur Urol 2016;69:211-2: Outcomes for Favorable and Unfavorable Intermediate Risk Prostate Cancer Patients Receiving Radiation Therapy With or Without Short-term Androgen Deprivation TherapyJustin C Voog, Rebecca Paulus, Jason A Efstathiou
European Urology|September 4, 2023
Reply to Thomas Seisen, Morgan Rouprêt, and Pierre Blanchard's Letter to the Editor re: Alexandre R. Zlotta, Leslie K. Ballas, Andrzej Niemierko, et al. Radical Cystectomy Versus Trimodality Therapy for Muscle-invasive Bladder Cancer: A Multi-institutional Propensity Score Matched and Weighted Analysis. Lancet Oncol 2023;24:669-81Alexandre R Zlotta, Katherine Lajkosz, Jason A Efstathiou
Oncology (Williston Park, N.Y.)|March 15, 2014
Proton radiotherapy for prostate cancer: how did we get here, and where do we go from here?James B Yu, Jason A Efstathiou, Justin E Bekelman
Asian Journal of Andrology|February 26, 2013
The opportunity cost of androgen suppression in locally advanced prostate cancerPhillip J Gray, Jason A Efstathiou, William U Shipley
Journal of Oncology Practice|August 15, 2013
Summary of oral abstract session B: innovating to improve care qualityJames A Hayman, Linda D Bosserman, Jason A Efstathiou
Hematology/Oncology Clinics of North America|April 4, 2015
Bladder preservation strategiesAshesh B Jani, Jason A Efstathiou, William U Shipley
Pageof 28